National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum β-lactamases

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 12, 2010, Pages 5099-5104

  Marchaim, Dror ^a   Gottesman, Tamar ^b   Schwartz, Orna ^b   Korem, Maya ^c   Maor, Yasmin ^e   Rahav, Galia ^e   Karplus, Rebekah ^f   Lazarovitch, Tsipora ^f   Braun, Eyal ^g   Sprecher, Hana ^g   Lachish, Tamar ^d   Wiener Well, Yonit ^d   Alon, Danny ⁱ   Chowers, Michal ⁱ   Ciobotaro, Pnina ^j   Bardenstein, Rita ^j   Paz, Alona ^h   Potasman, Israel ^h   Giladi, Michael ^a   Schechner, Vered ^a   Schwaber, Mitchell J ^a   Klarfeld Lidji, Shiri ^a   Carmeli, Yehuda ^a   more..

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d SHAARE ZEDEK MEDICAL CENTER   (Israel)

^e SHEBA MEDICAL CENTER   (Israel)

^f ASSAF HAROFEH MEDICAL CENTER   (Israel)

^g RAMBAM MEDICAL CENTER   (Israel)

^h BNAI ZION MEDICAL CENTER   (Israel)

ⁱ MEIR MEDICAL CENTER   (Israel)

^j KAPLAN MEDICAL CENTER   (Israel)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; CASE CONTROL STUDY; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; FEMALE; FUNCTIONAL STATUS; HOSPITAL ADMISSION; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; SEPTIC SHOCK;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649644716     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00565-10     Document Type: Article

References (38)

1. Ben-Ami, R., J. Rodriguez-Baño, H. Arslan, J. D. Pitout, C. Quentin, E. S. Calbo, O. K. Azap, C. Arpin, A. Pascual, D. M. Livermore, J. Garau, and Y. Carmeli. 2009. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin. Infect. Dis. 49:682-690.
2. Ben-Ami, R., M. J. Schwaber, S. Navon-Venezia, D. Schwartz, M. Giladi, I. Chmelnitsky, A. Leavitt, and Y. Carmeli. 2006. Influx of extended-spectrum beta-lactamase-producing Enterobacteriaceae into the hospital. Clin. Infect. Dis. 42:925-934.
3. Bin, C., W. Hui, Z. Renyuan, N. Yongzhong, X. Xiuli, X. Yingchun, Z. Yuanjue, and C. Minjun. 2006. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagn. Microbiol. Infect. Dis. 56:351-357.
4. Bion, J. F., S. A. Edlin, G. Ramsay, S. McCabe, and I. M. Ledingham. 1985. Validation of a prognostic score in critically ill patients undergoing transport. Br. Med. J. (Clin. Res. ed.) 291:432-434.
5. Borer, A., J. Gilad, G. Menashe, N. Peled, K. Riesenberg, and F. Schlaeffer. 2002. Extended-spectrum beta-lactamase-producing Enterobacteriaceae strains in community-acquired bacteremia in Southern Israel. Med. Sci. Monit. 8:CR44-CR47.
6. Brigante, G., F. Luzzaro, M. Perilli, G. Lombardi, A. Coli, G. M. Rossolini, G. Amicosante, and A. Toniolo. 2005. Evolution of CTX-M-type beta-lactamases in isolates of Escherichia coli infecting hospital and community patients. Int. J. Antimicrob. Agents 25:157-162.
7. Burgess, D. S., R. G. Hall II, J. S. Lewis II, J. H. Jorgensen, and J. E. Patterson. 2003. Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period. Pharmacotherapy 23:1232-1237.
8. Calbo, E., V. Romani, M. Xercavins, L. Gomez, C. G. Vidal, S. Quintana, J. Vila, and J. Garau. 2006. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J. Antimicrob. Chemother. 57:780-783.
9. Cantón, R., A. Novais, A. Valverde, E. Machado, L. Peixe, F. Baquero, and T. M. Coque. 2008. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 14(Suppl. 1):144-153.
10. Charlson, M. E., P. Pompei, K. L. Ales, and C. R. MacKenzie. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40:373-383.
11. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. Approved standard M100-S17. CLSI, Wayne, PA.
12. Colodner, R., W. Rock, B. Chazan, N. Keller, N. Guy, W. Sakran, and R. Raz. 2004. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur. J. Clin. Microbiol. Infect. Dis. 23:163-167.
13. Endimiani, A., F. Luzzaro, M. Perilli, G. Lombardi, A. Coli, A. Tamborini, G. Amicosante, and A. Toniolo. 2004. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin. Infect. Dis. 38:243-251.
14. Ho, P. L., W. M. Chan, K. W. Tsang, S. S. Wong, and K. Young. 2002. Bacteremia caused by Escherichia coli producing extended-spectrum betalactamase: a case-control study of risk factors and outcomes. Scand. J. Infect. Dis. 34:567-573.
15. Kang, C. I., S. H. Kim, D. M. Kim, W. B. Park, K. D. Lee, H. B. Kim, M. D. Oh, E. C. Kim, and K. W. Choe. 2004. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol. 25:860-867.
16. Katz, S., A. B. Ford, R. W. Moskowitz, B. A. Jackson, and M. W. Jaffe. 1963. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 185:914-919.
17. Kim, B. N., J. H. Woo, M. N. Kim, J. Ryu, and Y. S. Kim. 2002. Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. J. Hosp. Infect. 52:99-106.
18. Kim, Y. K., H. Pai, H. J. Lee, S. E. Park, E. H. Choi, J. Kim, J. H. Kim, and E. C. Kim. 2002. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob. Agents Chemother. 46:1481-1491.
19. Kiratisin, P., A. Apisarnthanarak, P. Saifon, C. Laesripa, R. Kitphati, and L. M. Mundy. 2007. The emergence of a novel ceftazidime-resistant CTX-M extended-spectrum beta-lactamase, CTX-M-55, in both community-onset and hospital-acquired infections in Thailand. Diagn. Microbiol. Infect. Dis. 58:349-355.
20. Kumar, A., D. Roberts, K. E. Wood, B. Light, J. E. Parrillo, S. Sharma, R. Suppes, D. Feinstein, S. Zanotti, L. Taiberg, D. Gurka, A. Kumar, and M. Cheang. 2006. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med. 34:1589-1596.
21. Marchaim, D., S. Navon-Venezia, M. J. Schwaber, and Y. Carmeli. 2008. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob. Agents Chemother. 52:1413-1418.
22. Marchaim, D., R. Zaidenstein, T. Lazarovitch, Y. Karpuch, T. Ziv, and M. Weinberger. 2008. Epidemiology of bacteremia episodes in a single center: increase in Gram-negative isolates, antibiotics resistance, and patient age. Eur. J. Clin. Microbiol. Infect. Dis. 27:1045-1051.
23. Navon-Venezia, S., O. Hammer-Munz, D. Schwartz, D. Turner, B. Kuzmenko, and Y. Carmeli. 2003. Occurrence and phenotypic characteristics of extended-spectrum beta-lactamases among members of the family Enterobacteriaceae at the Tel-Aviv Medical Center (Israel) and evaluation of diagnostic tests. J. Clin. Microbiol. 41:155-158.
24. Paterson, D. L. 2000. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin. Microbiol. Infect. 6:460-463.
25. Paterson, D. L., W. C. Ko, A. Von Gottberg, J. M. Casellas, L. Mulazimoglu, K. P. Klugman, R. A. Bonomo, L. B. Rice, J. G. McCormack, and V. L. Yu. 2001. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J. Clin. Microbiol. 39:2206-2212.
26. Paterson, D. L., W. C. Ko, A. Von Gottberg, S. Mohapatra, J. M. Casellas, H. Goossens, L. Mulazimoglu, G. Trenholme, K. P. Klugman, R. A. Bonomo, L. B. Rice, M. M. Wagener, J. G. McCormack, and V. L. Yu. 2004. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin. Infect. Dis. 39:31-37.
27. Pitout, J. D., and K. B. Laupland. 2008. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 8:159-166.
28. Pitout, J. D., P. Nordmann, K. B. Laupland, and L. Poirel. 2005. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J. Antimicrob. Chemother. 56:52-59.
29. Rodriguez-Baño, J., J. C. Alcala, J. M. Cisneros, F. Grill, A. Oliver, J. P. Horcajada, T. Tortola, B. Mirelis, G. Navarro, M. Cuenca, M. Esteve, C. Pena, A. C. Llanos, R. Canton, and A. Pascual. 2008. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch. Intern. Med. 168:1897-1902.
30. Rodriguez-Baño, J., and M. D. Navarro. 2008. Extended-spectrum beta-lactamases in ambulatory care: a clinical perspective. Clin. Microbiol. Infect. 14(Suppl. 1):104-110.
31. Rodriguez-Baño, J., M. D. Navarro, L. Romero, M. A. Muniain, M. de Cueto, M. J. Rios, J. R. Hernandez, and A. Pascual. 2006. Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin. Infect. Dis. 43:1407-1414.
32. Rodriguez-Baño, J., E. Picon, P. Gijon, J. R. Hernandez, M. Ruiz, C. Pena, M. Almela, B. Almirante, F. Grill, J. Colomina, M. Gimenez, A. Oliver, J. P. Horcajada, G. Navarro, A. Coloma, and A. Pascual. 2010. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin. Infect. Dis. 50:40-48.
33. Sahly, H., S. Schubert, J. Harder, M. Kleine, D. Sandvang, U. Ullmann, J. M. Schroder, and R. Podschun. 2006. Activity of human beta-defensins 2 and 3 against ESBL-producing Klebsiella strains. J. Antimicrob. Chemother. 57:562-565.
34. Schechner, V., V. Nobre, K. S. Kaye, M. Leshno, M. Giladi, P. Rohner, S. Harbarth, D. J. Anderson, A. W. Karchmer, M. J. Schwaber, and Y. Carmeli. 2009. Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected? Clin. Infect. Dis. 48:580-586.
35. Schwaber, M. J., and Y. Carmeli. 2007. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J. Antimicrob. Chemother. 60:913-920.
36. Schwaber, M. J., S. Navon-Venezia, K. S. Kaye, R. Ben-Ami, D. Schwartz, and Y. Carmeli. 2006. Clinical and economic impact of bacteremia with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 50:1257-1262.
37. Talbot, G. H., J. Bradley, J. E. Edwards, Jr., D. Gilbert, M. Scheld, and J. G. Bartlett. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42:657-668.
38. Yumuk, Z., G. Afacan, M. H. Nicolas-Chanoine, A. Sotto, and J. P. Lavigne. 2008. Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15. J. Antimicrob. Chemother. 62:284-288.